Abstract
More than half of adults with epilepsy undergoing resective epilepsy surgery achieve long-term seizure freedom and might consider withdrawing antiseizure medications (ASMs). We aimed to identify predictors of seizure recurrence after starting postoperative ASM withdrawal and develop and validate predictive models.
We performed an international multicentre observational cohort study in nine tertiary epilepsy referral centres. We included 850 adults who started ASM withdrawal following resective epilepsy surgery and were free of seizures other than focal non-motor aware seizures (auras) before starting ASM withdrawal. We developed a model predicting recurrent seizures, other than auras, using Cox proportional hazards regression in a derivation cohort (n=231). Independent predictors of seizure recurrence, other than auras, following the start of ASM withdrawal were focal-aware seizures after surgery and before withdrawal (adjusted hazards ratio [aHR] 5.5, 95% confidence interval [CI] 2.7-11.1), history of focal to bilateral tonic-clonic seizures before surgery (aHR 1.6, 95% CI 0.9-2.8), time from surgery to the start of ASM withdrawal (aHR 0.9, 95% CI 0.8-0.9), and number of ASMs at time of surgery (aHR 1.2, 95% CI 0.9-1.6). Model discrimination showed a concordance statistic of 0.67 (95% CI 0.63-0.71) in the external validation cohorts (n=500). A secondary model predicting recurrence of any seizures (including auras) was developed and validated in a subgroup that did not have auras before withdrawal (n=639), showing a concordance statistic of 0.68 (95% CI 0.64-0.72). Calibration plots indicated high agreement of predicted and observed outcomes for both models.
We show that simple algorithms, available as graphical nomograms and online tools (predictepilepsy.github.io), can provide probabilities of seizure outcomes after starting postoperative ASMs withdrawal. These multicentre-validated models may assist clinicians when discussing ASM withdrawal after surgery with their patients.
Competing Interest Statement
MG reports fees and travel support from Bial pharmaceutical and Nestle Health Science outside the submitted work. PP has received speaker honoraria or consultancy fees to his institution from Chiesi, Eisai, LivaNova, Novartis, Sun Pharma, Supernus, and UCB Pharma, outside the submitted work. He is an Associate Editor for Epilepsia Open. JSD is on the Editorial Board of Annals of Neurology. JWS has received speaker honoraria or consultancy fees from Eisai, UCB Pharma, Arvelle and Zogenix Pharma; grants from Eisai, UCB Pharma outside the submitted work and is on the Editorial Board of the Lancet Neurology, ST is supported by the Susan S Spencer Clinical Research Training Scholarship and the Michigan Institute for Clinical and Health Research J Award UL1TR002240.
Funding Statement
No funding was received towards this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Joint Ethics Committee of the National Hospital for Neurology and Neurosurgery and University College London Institute of Neurology of London Waived ethical approval for this work. Hospital de Santa Maria Comite de Etica of Lisbon Waived ethical approval for this work. Uniepilepsias Instituto Roosevelt Comite de Etica of Bogota Waived ethical approval for this work. Local Clinial Audit Oxford University. Hospital Trust internal committee of Oxford Approved ethical approval for this work. University of Cape Town Human Research Ethics Committee of Cape Town Approved ethical approval for this work. Melbourne Health and Royal Childrens Hospital Human Research Ethics Committees of Melbourne Approved ethical approval for this work. Continuous Service Improvement Office and Vale University Health Board of Cardiff Approved ethical approval for this work. Shenzhen Children Hospital Ethics Committee of Shenzhen Waived ethical approval for this work. Cleveland Clinics Institutional Review Board of Cleveland Approved ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Figures and Tables
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Abbreviations
- ASM
- AntiSeizure Medication
- IQR
- Interquartile Range
- ILAE
- the International League Against Epilepsy
- HR
- Hazard Ratio
- aHR
- Adjusted Hazard Ratio
- MRI
- Magnetic Resonance Imaging
- EEG
- Electroencephalogram
- AIC
- Akaike Information Criterion
- FBTCS
- Focal to Bilateral Tonic Clonic Seizures
- WAMS
- Withdrawal of Antiseizure Medication After Surgery
